Dr Richard Maziarz speaks to ecancer at ASH 2018 about follow-up results from the JULIET trial for patients with relapsed or treatment-resistant diffuse large B-cell lymphoma (DLBCL).
He reports that 18 months after treatment with product tisagenlecleucel, patients with relapsed or treatment-resistant diffuse large B-cell lymphoma continue to show a high response rates.
Dr Richard Maziarz also explains the adverse effects of the treatment, as well as the potential implications - which he describes as changing the natural history of the disease.
What his press conference here.
Read the article here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.